Home pageJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
172,12 $
After Hours:(0,00%)0,00
172,12 $
Data e ora chiusura: 1 dic, 18:21:56 GMT-5 · USD · NASDAQ · Disclaimer
Chiusura precedente
176,53 $
Intervallo giornaliero
170,57 $ - 175,55 $
Intervallo annuale
95,49 $ - 182,99 $
Cap di mercato
10,46 Mld USD
Volume medio
1,22 Mln
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
NASDAQ
Dati finanziari
Conto economico
Entrate
Utile netto
| (USD) | set 2025info | Variazione Y/Y |
|---|---|---|
Entrate | 1,13 Mld | 6,74% |
Spese di gestione | 745,72 Mln | 9,16% |
Utile netto | 251,41 Mln | 16,91% |
Margine di profitto netto | 22,33 | 9,57% |
Utili per azione | 8,13 | 23,00% |
EBITDA | 429,76 Mln | 1,01% |
Aliquota fiscale effettiva | -2.697,20% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (USD) | set 2025info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 2,05 Mld | -21,85% |
Totale attivo | 11,36 Mld | -7,34% |
Totale passivo | 7,40 Mld | -8,50% |
Patrimonio netto totale | 3,96 Mld | — |
Azioni in circolazione | 60,77 Mln | — |
Prezzo/valore contabile | 2,71 | — |
Redditività dell'attivo | 5,64% | — |
Rendimento sul capitale | 6,79% | — |
Flusso di cassa
Flusso di cassa netto
| (USD) | set 2025info | Variazione Y/Y |
|---|---|---|
Utile netto | 251,41 Mln | 16,91% |
Liquidità di esercizio | 474,62 Mln | 19,03% |
Contanti da investimenti | -327,80 Mln | -253,12% |
Contanti da finanziamenti | -10,83 Mln | -104,39% |
Flusso di cassa netto | 136,19 Mln | -84,21% |
Flusso di cassa libero | 466,35 Mln | 56,12% |
Informazioni
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Fondazione
2003
Sito web
Dipendenti
2.800
